SYNCOM FORMULATIONS (INDIA)
Back to Balance Sheet
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹416 Cr | ₹407 Cr | ₹378 Cr | ₹308 Cr | ₹184 Cr |
What is the latest Total Liabilities ratio of SYNCOM FORMULATIONS (INDIA) ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹416 Cr |
| Mar2024 | ₹407 Cr |
| Mar2023 | ₹378 Cr |
| Mar2022 | ₹308 Cr |
| Mar2017 | ₹184 Cr |
How is Total Liabilities of SYNCOM FORMULATIONS (INDIA) Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹416 Cr | 2.18 | |
| Mar2024 | ₹407 Cr | 7.69 | |
| Mar2023 | ₹378 Cr | 22.58 | |
| Mar2022 | ₹308 Cr | 67.59 | |
| Mar2017 | ₹184 Cr | - | |
Compare Total Liabilities of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,254.9 Cr | 0.5% | -5.1% | -25.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -1.5% | 2.5% | 14.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹221,666.0 Cr | 7.4% | 22.2% | 26.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,108.0 Cr | 3.1% | 4.3% | 38.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.6% | -1.4% | -6.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,990.9 Cr | 1.5% | -15.2% | -9.1% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | 0.5% |
-5.1% |
-25.3% |
| SENSEX | 1.2% |
0.4% |
-2.9% |
You may also like the below Video Courses